Navigate
Home
Join
Renew
About Us
Mission & Vision
Board of Directors
Staff
Diversity & Inclusion
Press Room
Get Inolved
Find an MFM Subspecialist
Committees
Annual Reports
Clinical Guidance
Clinical Publications & Guidelines
Patient Safety and Quality Resources
Reproductive Health
COVID-19
Mpox (Monkeypox) Guidance
Clinical Informatics
Publish Your Research
MFM Fellowship
Advocacy
Advocacy Hub
Support Abortion Access
Coalition to Advance Maternal Therapeutics
Maternal Mortality Scorecard
For Patients & Families
Education & Events
2023 Annual Meeting
In-Person Events
e-Learning
SMFM Bookstore
Practice Management
Online Coding Resources
Consulting Services
Telehealth
Webinars
Contemporary Guide to Practice Management
SMFM Bookstore
Stay Connected
SMFM Membership
Press Room
Member Spotlight
Exhibit & Sponsor
Online Communities
Special Delivery e-Newsletter
Newsroom
Career Opportunities
Contact
Foundation for SMFM
Career Center
Contact Us
Facebook
Twitter
C
Login
|
Join
Search
Search
Home
»
Publications & Guidelines
» SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention o...
SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth
Tags:
preterm birth
,
prior preterm birth
Categories:
SMFM Statement
back
